Minocycline Medicine 04 December 2025 Extended indication Minocycline monotherapy for treatment of moderate to severe inflammatory lesions of Papulopustular rosacea in adults and elderly. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Minocycline Domain Chronic immune diseases Reason of inclusion New medicine (specialité) Main indication Skin diseases Extended indication Minocycline monotherapy for treatment of moderate to severe inflammatory lesions of Papulopustular rosacea in adults and elderly. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Journey Medical Portfolio holder Journey Medical Mechanism of action Antibiotic Route of administration Oral Therapeutical formulation Tablet Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP Submission date August 2025 Expected Registration September 2026 Orphan drug Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References NHG-Standaard Rosacea (2019); CBS bevolkingsdata; Two et al., J Am Acad Dermatol, 2015. Additional remarks Ongeveer 5% van de Nederlandse volwassenen heeft rosacea, waarvan circa 30 tot 40% papulopustuleuze rosacea. Hiervan heeft naar schatting 20 tot 30% matige tot ernstige vormen die in aanmerking komen voor systemische therapie. Dit betekent dat jaarlijks ongeveer 40.000 tot 75.000 patiënten in Nederland mogelijk behandeld worden met orale middelen zoals minocycline. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks